Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron ... sozinibercept, a VEGF 'trap' compound that ...

While Regeneron remains confident that Eylea HD sales will continue to grow over time, copay problems and off-label Avastin use aren’t all there is to the saga of the VEGF franchise’s recent ...

Regeneron's drug, called VEGF Trap-Eye, treats wet age-related macular degeneration and goes before a Food and Drug Administration advisory panel Friday. Regeneron's treatment has proved effective ...

Shares of Regeneron Pharmaceuticals (NASDAQ ... The standard version of the anti-VEGF intravitreal injection delivered $1.4B in net product sales for the company in Q1, indicating a ~29% YoY ...

Regeneron said Eylea’s net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars ...

Increased market share of off-label Avastin poses a challenge to the anti-VEGF category ... and potential delays in key product approvals. Regeneron faced mixed results in Q1 2025 with challenges ...